Elomotecan (TFA)
Product Specifications
UNSPSC Description
Elomotecan TFA is a potent inhibitor of topoisomerases I and II. Elomotecan TFA is a camptothecin analog belonging to the homocamptothecin family (hCPT). Elomotecan TFA reduces the proliferation of different tumor cells with higher potency than other anticancer agents of reference targeting topoisomerases I and II[1].
Target Antigen
Topoisomerase
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/elomotecan-tfa.html
Smiles
O=C(OC1)C[C@](O)(CC)C2=C1C(N3CC4=C(CN5CCC(C)CC5)C6=CC(C)=C(Cl)C=C6N=C4C3=C2)=O.OC(C(F)(F)F)=O
Molecular Weight
636.06
References & Citations
[1]Trocóniz IF, et al. Population pharmacokinetic/pharmacodynamic modeling of drug-induced adverse effects of a novel homocamptothecin analog, elomotecan (BN80927), in a Phase I dose finding study in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2012;70(2):239-250.
Shipping Conditions
Room temperature
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-13622B/Elomotecan-TFA-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-13622B/
Clinical Information
Phase 1
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
![Human Lung Adenocarcinoma Cells [NCI-H1395 Cells]](https://cdn.genprice.uk/genprice/genprice3.png)
